White Papers
-
Making Clinical Research Better For Patients With Patient Centricity By Design
6/13/2023
Discover why many sponsors struggle to design and conduct studies that accommodate the perspectives and preferences of patients and caregivers.
-
The State Of Black Participation In Clinical Trials
2/24/2023
The need to design trials enrolling more demographically diverse patients is widely recognized. Learn why implementing effective, sustainable, and scalable enrollment diversity strategies remains a challenge for biopharmaceutical companies.
-
Synthetic Control Arm In Clinical Trials
12/8/2022
Get an overview of the SCA, an external control generated with the goal of improving the interpretation of uncontrolled trials, which can enable better product development decisions.
-
Site Perspectives On Decentralized Clinical Trials
11/15/2022
Discover why understanding clinical research sites’ experiences and perspectives on DCTs will help industry stakeholders refine trial design, operational procedures, and regulatory policy to better serve patients and sites.
-
Hassle-Free Imaging In Clinical Trials
6/14/2022
In this paper, writers ask readers to consider how far the field of imaging has transpired in recent times, as well as explore the latest innovations, and contemplate what possibilities lie ahead.
-
DCTs: What Are They And What Are The Direct Impacts To DMs?
1/21/2022
In 2020, the need for alternative approaches to clinical trial execution and data capture became a reality overnight. The concept of implementing components of decentralization within a clinical trial became one of ‘here and now,’ versus a concept of the future.
-
Advancing DCTs Through A Unified Approach To eCOA And DHTs
7/6/2021
Digital health technologies and assessments of patient-reported outcomes are on the rise. Read how uniting the two can better inform how patients experience their disease and respond to treatment.
-
Transform Your Drug Safety Data And Adjudication Processes With Technology
7/6/2021
Many may not know that cloud platforms can help streamline clinical endpoint adjudication. Read below to see how these play a role in cutting costs, improving data quality, smoothing regulatory approval, and speeding time to market.
-
The Growth Of Phase IV Trials And The Need To Demonstrate Effectiveness Using Electronic Patient Reported Outcomes
7/10/2020
This paper addresses and describes the growing need to satisfy the value perception of multiple stakeholders and the importance of Late Phase trials capturing Clinical Outcome Assessments (COA) and electronic Patient Reported Outcomes (ePRO) in relation to this.